Pall T. Onundarson Urges You to Watch It: Emerging Anticoagulants and Reversal Agents What’s Next in the Pipeline?
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, recently shared on LinkedIn, reposting from Anticoagulation Forum:
”Something to think about. Great savings if you want them.”
Anticoagulation Forum posted on Emerging Anticoagulants on LinkedIn:
‘Missed it live? Now’s your chance to catch up — or rewatch! The recording of our recent webinar, Emerging Anticoagulants and Reversal Agents: What’s Next in the Pipeline?, is now available! Watch it here.
As the anticoagulation field continues to evolve, this session delivers expert insights into investigational agents and reversal strategies that may soon impact clinical practice. If you manage complex patients or influence clinical policy, this is one to watch.
Webinar highlights:
- Latest clinical trial data
- Future applications in stroke prevention, dialysis, oncology, and device-related thrombosis
- Practical considerations for frontline care and system-level planning
We are grateful to our speakers and panelists for a fantastic discussion:
Geoffrey Barnes, MD, MSc
Gabe Fontaine PharmD, MBA, BCCCP, BCPS, FNCS, FCCM
Jean Connors, MD
Arthur Allen, PharmD, CACP (Moderator)
Jori May, MD (Moderator)
Free for AC Forum members — membership is quick and free to join. Explore this and hundreds of additional resources to enhance your practice.”
Join AC Forum.
Stay tuned to not miss out on all webinars in the field of coagulation with Hemostasis Today.
-
Aug 4, 2025, 06:00Genotype–Phenotype Understanding in Hemophilia B: Commentary on Factor IX Missense Variants
-
Aug 4, 2025, 05:47National Health Center Week – Recognizing the Vital Role of HTCs in Specialized Care
-
Aug 4, 2025, 05:33Women with Hemophilia Finally Heard: “DISMISSED” Premieres August 22
-
Aug 4, 2025, 04:58Women with Inherited Bleeding Disorders: Overcoming Diagnostic and Clinical Challenge
-
Aug 4, 2025, 01:37EAHAD Launches Italian Booklet to Support Young Girls With Bleeding Disorders During Their First Period
-
Aug 4, 2025, 01:59Michael Makris Posts Haemophilia Journal Article Reassessing UK Blood Inquiry
-
Aug 4, 2025, 01:09Manuel Monreal Congratulates Authors Ahead of JTH Publication: VTE-Predict Score Validated in RIETE Cohort
-
Aug 3, 2025, 17:48Nathan Connell: What Is The "Mild Equivalent" For Hemophilia A That Is Achieved While on Emicizumab?
-
Aug 3, 2025, 03:54Cedric Hermans on the Inspiring Impact of the WFH Humanitarian Aid Program Worldwide
-
Aug 2, 2025, 20:14Sebastian Szmit Shares Patients’ Perspectives on Decision‑Making for Antithrombotic Therapy in Advanced Cancer
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 4, 2025, 05:20NBCA: Alexis’s DVT Diagnosis Came Without Warning - Learn How She Caught It Early
-
Aug 4, 2025, 00:50NBCA: After Losing Her Daughter to a Blood Clot, Charita Fights to Save Others
-
Aug 3, 2025, 18:10Andrew Agwunobi Congrats Dr. Oladipo Cole and The Whole Team at the Connecticut Bleeding Disorder Center
-
Aug 3, 2025, 12:03Elias Bouchi Presents Werfen EEMEA Talks on Hemostasis: Clot Stories Season 3
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab